| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accounting for Heterogeneity in Resource Allocation Decisions: Methods and Practice in UK Cancer Technology Appraisals
|
Ward, Thomas
|
|
|
24 |
7 |
p. 995-1008
|
artikel
|
| 2 |
Author’s Reply
|
Nguyen, Joehl T.
|
|
|
24 |
7 |
p. 1086-1087
|
artikel
|
| 3 |
Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies
|
Fornaro, Giulia
|
|
|
24 |
7 |
p. 1045-1058
|
artikel
|
| 4 |
Catalog of Age- and Medical Condition—Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis
|
Jiao, Boshen
|
|
|
24 |
7 |
p. 957-965
|
artikel
|
| 5 |
Considerations for Cost-Effectiveness Analysis in Oncology
|
Cho, Sang Kyu
|
|
|
24 |
7 |
p. 1084-1085
|
artikel
|
| 6 |
Copyright/Subscription
|
|
|
|
24 |
7 |
p. v
|
artikel
|
| 7 |
Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia
|
van den Berg, Sibren
|
|
|
24 |
7 |
p. 925-929
|
artikel
|
| 8 |
Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England
|
Boriani, Giuseppe
|
|
|
24 |
7 |
p. 930-938
|
artikel
|
| 9 |
Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland
|
O Murchu, Eamon
|
|
|
24 |
7 |
p. 948-956
|
artikel
|
| 10 |
Cost-Effectiveness of Propofol (Diprivan) Versus Inhalational Anesthetics to Maintain General Anesthesia in Noncardiac Surgery in the United States
|
Kampmeier, Tim
|
|
|
24 |
7 |
p. 939-947
|
artikel
|
| 11 |
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
|
Onuoha, Erica N.
|
|
|
24 |
7 |
p. 1068-1083
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
24 |
7 |
p. vi
|
artikel
|
| 13 |
Evaluating Complex Health and Social Care Program Using Multi-Criteria Decision Analysis: A Case Study of “Better Together in Amsterdam North”
|
Karimi, Milad
|
|
|
24 |
7 |
p. 966-975
|
artikel
|
| 14 |
Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study
|
Petersohn, Svenja
|
|
|
24 |
7 |
p. 983-994
|
artikel
|
| 15 |
Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis
|
Mok, Chiu Hang
|
|
|
24 |
7 |
p. 1059-1067
|
artikel
|
| 16 |
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare
|
Walraven, Jelle
|
|
|
24 |
7 |
p. 1038-1044
|
artikel
|
| 17 |
“Looking Under the Hood” of Anchor-Based Assessment of Clinically Important Change: A Machine Learning Approach
|
Schwartz, Carolyn E.
|
|
|
24 |
7 |
p. 1009-1015
|
artikel
|
| 18 |
Measuring Attitudes About Genomic Medicine: Validation of the Genomic Orientation Scale (GO Scale)
|
Horrow, Caroline
|
|
|
24 |
7 |
p. 1030-1037
|
artikel
|
| 19 |
Measuring Patient Preferences at the FDA Center for Devices and Radiological Health: Reflections and Projections
|
Webber, Christina M.
|
|
|
24 |
7 |
p. 1024-1029
|
artikel
|
| 20 |
Table of Contents
|
|
|
|
24 |
7 |
p. i-iv
|
artikel
|
| 21 |
Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation
|
Lipman, Stefan A.
|
|
|
24 |
7 |
p. 976-982
|
artikel
|
| 22 |
Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019
|
Gnanasakthy, Ari
|
|
|
24 |
7 |
p. 1016-1023
|
artikel
|
| 23 |
Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases
|
Zawadzki, Roy S.
|
|
|
24 |
7 |
p. 917-924
|
artikel
|
Tijdschrift beschrijving